Drug Profile
OSX 200
Alternative Names: OSX200Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Ossianix
- Class
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Duchenne muscular dystrophy
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA